ePrints

Getting the levothyroxine (LT4) dose right for adults with hypothyroidism: opportunities and challenges in the use of modern LT4 preparations

Lookup NU author(s): Dr Salman Razvi

Downloads

• Published version [.pdf]

Licence

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND).

Abstract

© 2022 Merck Healthcare KGaA. Published by Informa UK Limited, trading as Taylor & Francis Group. Lifelong treatment with levothyroxine (LT4) is the mainstay of management for individuals with hypothyroidism. Many hypothyroid patients start LT4 treatment at a low dose (e.g. 25–50 µg), especially the elderly, those with residual thyroid function, those with low body weight, and those with significant (especially cardiac) comorbidities. Almost half of patients on LT4 replacement therapy demonstrate either under- or over-treatment. Many LT4 preparations have relatively large intervals between tablet strengths at the lower end of their dose ranges (providing 25 µg, 50 µg, and 75 µg tablets), which may represent a barrier to achieving the optimum maintenance treatment for some patients. The availability of intermediate tablet strengths of LT4 in the 25–75 µg range may facilitate precise and effective dose titration of LT4 and may also enable convenient maintenance regimens based on a single LT4 tablet daily, to support adherence to therapy.

Publication metadata

Author(s): Gottwald-Hostalek U, Razvi S

Publication type: Review

Publication status: Published

Journal: Current Medical Research and Opinion

Year: 2022

Volume: 38

Issue: 11

Pages: 1865-1870

Online publication date: 12/05/2022

Acceptance date: 25/04/2022

ISSN (print): 0300-7995

ISSN (electronic): 1473-4877

Publisher: Taylor and Francis Ltd.

URL: https://doi.org/10.1080/03007995.2022.2071059

DOI: 10.1080/03007995.2022.2071059

PubMed id: 35484983

Share